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Long-term efficacy and toxicity
results of the FLUMIZ trial
(fludarabine and mitoxantrone
followed by yttrium-90
ibritumomab tiuxetan in
untreated follicular lymphoma)
The radiosensitivity of lymphomas as well as the local targeted
delivery of high doses of radiation make radioimmunotherapy
(RIT) an attractive therapeutic option. RIT is indeed an
underestimated tool. In follicular lymphoma (FL), RIT
represents one of the most effective single agents. The two most
commonly used radioimmunoconjugates are 90Y-ibritumomab
tiuxetan (Zevalin) and 131I-tositumomab, both based on
murine anti-Cd20 antibodies.
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RIT has demonstrated efficacy in relapsed/refractory FL
and was approved for this indication [1]. Subsequently, many
trials have evaluated the role of RIT consolidation after
initial tumor debulking with chemotherapy or
immunochemotherapy [2] and several phase II studies
supported these results [3–5].
We now report updated long-term efficacy and toxicity results
of a multicenter nonrandomized phase II trial of fludarabine and
mitoxantrone plus RIT (fludarabine, mitoxantrone, zevalin
trial), demonstrating that this combination was safe and very
effective in untreated FL patients.
Sixty-one patients with stage III and IV untreated FL were
enrolled between June 2004 and April 2006, at 13 Italian
institutions. Briefly, treatment schedule was the following:
40 mg/m2 oral fludarabine (F) on days 1–3, 10 mg/m2 i.v.
mitoxantrone (N) on day 1 every 28 days for six cycles
(FN regimen), followed by one course of Zevalin, which
consisted in 2 weekly infusions of 250 mg/m2 rituximab
followed by a weight-based dose of 90Y-ibritumumab tiuxetan.
Primary end points at the time of the first analysis were
complete response and hematological toxic effects, and
secondary end points were overall survival (OS) and
progression-free survival (PFS). Fifty-seven patients were
treated with RIT after the completion of six courses of FN
regimen (four patients were excluded due to disease
progression and bone marrow infiltration >25%). Median
follow-up at the time of the last analysis was 64 months (range
35–87). Six-year PFS was estimated to be 68.0% (Figure 1A),
and 6-year OS was estimated to be 93.0% (Figure 1B).
Noteworthy, late hematological side effects such as
myelodisplastic syndromes or acute myeloid leukemias did not
occurred so far. All patients had a complete hematological
recovery after the completion of the sequential treatment.
Sixteen patients relapsed during the follow-up period and four
patients died due to disease progression. Twenty-two patients
(38%) are in continuous complete remission after >4 years of
follow-up. All relapsed patients underwent second-line
chemotherapy and high-dose chemotherapy (stem cell rescue
was performed in four patients).
These results confirm the long-term efficacy and safety of six
cycles of fludarabine and mitoxantrone followed by
consolidation with 90Y-ibritumumab tiuxetan: the 6-year PFS
and OS are comparable to the ones reported for
chemoimmunotherapy alone in untreated FL and no increased
incidence of secondary hematologic malignancies was observed.
Consolidation with RIT is an innovative treatment approach
which increases the rate of complete remission and maximizes
the length of first remission.
In particular, in this study, sequential treatment with
fludarabine-containing regimen and RIT did not give rise to
cumulative toxicity, in terms of a good hematologic recovery
and, overall, of a significant possibility of mobilizing the
peripheral stem cells.
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